Investment Q&A

Q: Would you please give me your evaluation of FLGT's recent quarter. On the surface it appears quite positive, however the stock is down 10%. Was it their guidance that turned the market sour? I am also perplexed - they state they carry $28/share in cash and marketable securities yet the stock is trading at $23 implying that when you strip out cash the business is worth NEGATIVE $148,000,000. Does this mean the market believes something is fundamentally wrong with the business and/or management? Finally, as a shareholder should I be running for the hills or is this a case of the market mispricing an asset?

Many thanks
Scott

Q: Hello, you recommended UnitedHealth Group Inc. (UNH) in the past. The recent launch of an antitrust investigation against UNH has led to a sudden drop in the stock price. I’m curious about your thoughts on this investigation. Do you believe it will cause any damage to the company? And considering the circumstances, do you still consider UNH a good buy? Thank you!

Q: How would you rate ILMN overall since 2024? Is it still a takeover target in your estimation and who would be the top ones that would make most sense to acquire ILMN?

Q: Can i get you opinion on TMDX after their latest results? As well, could you please give me your favorite healthcare stocks? And rank them for order of purchase today. Thanks

Q: Hi 5i, this company recently tried to sell itself and there were no takers. They now have decided to let go of 25% of the workforce and buy up to 150 million dollars of shares back.

Looks like they will be cash flow positive by next quarter and are starting to get better traction on selling the drug.

The drug patent is for dosing as the chemical composition expires in a couple years. How would you value this company and would you rate it a buy hold or sell.

Q: On January 9, 2024, LNTH reported preliminary Fiscal 2023 Revenue between $1.295 – $1.297B. The stock price dropped from $65.30 to around $51 over 10 days. Lantheus reported 4Q on February 22 and the stock price jumped 14.71%. 2023 Revenue was $1.3B. 2024 Revenue guidance is $1.41 - $1.445B, with Adjusted diluted EPS guidance of $6.50 - $6.70. This about 7% revenue and 4% - 7% EPS annual growth. Adjusted 4Q EPS was $1.47 beat estimate of $1.45. Using 2023 Adjusted EPS, the P/E is 9. My questions are:

1) The 14.71% price jump brought the stock price back up the level it was before January 9, 2024 announcement. I am trying to understand the market action – would you please explain or best guess?

2) In your answers to Kel question on February 7, 2024 and Neil’s question on January 9, 2024, it was mentioned LNTH growth rate has slowdown, “The company has been reinvesting heavily in the last two years to pursue growth.” The 4Q result and 2024 guidance confirm growth has slowdown. Is this a value trap? Do you think the stock price would be stagnant for awhile until growth is reestablish?

Thank you.

Q: What's up TDOC? Sliding despite a significant improvement in earnings etc. The ratios are still overly optimistic?? Appreciate your comments.

Q: The 5i profile on Cipher Pharma lists only 5 employees - how accurate and current are such numbers? Also you dropped coverage on this stock in 2018 "until some visibility emerges." which now seems to be clear, would you consider recovering?

Q: What inning are each of these companies in (in terms of total return for an investor buying today), and are they both appropriate for a 3-5 year holding period?

Thank you

Q: Can you contrast SYK and ISRG? Are they competing against each other?

Q: Please comment on the recent earnings? Also can you provide a good substitute for this stock?

Q: your comments on qipt earnings please.
thanks

Q: could you give me your recent thoughts on VEEV please. I own LLY and WELL as well in healthcare but have recently been thinking of replacing VEEV with ISRG. I plan to give WELL more time at least until small caps show more improvement.

Q: I just sold DXCM and am looking for a replacement in the healthcare sector. I've either owned (ISRG, MASI) or watched (DHR) for years, but currently do not own any of these. From my end, they all look like good choices, which would be your preference and why?

If you've got another recommendation, I'm all ears!

Q: What do you think of this company for the next few years
Thank You
Peter

Q: Can you give your comments around INMD's earnings release. Seems they expecting more conservative quarters, rev dropped, but not all bad and close to expected. They now have close to 1/3 of their market cap in cash, yet still no buybacks or plan. I'm wondering if things are starting to look bad here or just a bump in the road and you'd still hold? Thx

Q: Your comment on earnings please, I have a small position in it, is it a sell, hold or buy more?
Thank you

Selina

Q: I Have exposure to all the sectors in TSX index in my non-registered account. All my investments are in Canadian companies except technology and health sector. I chose American equities for health sector because I did not think Canadian sector was true health sector. Instead I bought IBB-Q and VHT-A. What do think of my strategy? What do you think of the ETFs that I have in this health sector? What would be some alternatives?

Q: Hello 5i
Do you have any recent information or feelings about Novavax. I don't know if they have other exciting things in their vaccine pipeline or if they just missed the boat? Fortunately I'm "asking for a friend" looking at the chart NVAX has made money disappear for 3 years at an extraordinary pace.
Thanks as always! You have been a great resource !
Richard

Q: From the media: “ Amgen stock slouched Wednesday after a Lilly exec called the company's early-stage test results for a weight-loss drug "a bit underwhelming."

Huh? What did they expect a competitor to say? I thought the quarterly results were good and the new drug seems quite promising.

What is 5i's take on the AMGN recent quarter (which beat) and future prospects? Wouldn’t it be better to buy AMGN after the sell-off than pay the overhyped price commanded by LLY?